Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer

Medical Oncology

Volumn 31, Issue 10, 2014, Pages 1-5

  Jin, Hong ^a   Liang, Yundan ^b   Wang, Xunli ^c   Zhu, Jingqiang ^c   Sun, Ruifen ^a   Chen, Peng ^a   Nie, Xinwen ^a   Gao, Linbo ^a,d   Zhang, Lin ^a,d  

^a SICHUAN UNIVERSITY   (China)

^b YUNNAN MINZU UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

KRAS; Let 7; Papillary thyroid cancer; Polymorphism

Indexed keywords

TUMOR MARKER; KRAS PROTEIN, HUMAN; MICRORNA; MIRNLET7 MICRORNA, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ARTICLE; BINDING SITE; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; HUMAN; KRAS GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID CANCER; CARCINOMA; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID TUMOR;

ADULT; CARCINOMA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; THYROID NEOPLASMS;

EID: 84919905013     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0221-3     Document Type: Article

References (31)

1. Pazaitou-Panayiotou K, Iliadou PK, Chrisoulidou A, Mitsakis P, Doumala E, et al. The increase in thyroid cancer incidence is not only due to papillary microcarcinomas: a 40-year study in 1 778 patients. Exp Clin Endocrinol Diabetes. 2013;121(7):397–401.
2. Ostroumova E, Gudzenko N, Brenner A, Gorokh Y, Hatch M, et al. Thyroid cancer incidence in Chornobyl liquidators in Ukraine: SIR analysis, 1986–2010. Eur J Epidemiol. 2014.
3. Richardson DB. Exposure to ionizing radiation in adulthood and thyroid cancer incidence. Epidemiology. 2009;20(2):181–7.
4. Ivanov VK, Gorski AI, Tsyb AF, Maksioutov MA, Tumanov KA, et al. Radiation-epidemiological studies of thyroid cancer incidence among children and adolescents in the Bryansk oblast of Russia after the Chernobyl accident (1991–2001 follow-up period). Radiat Environ Biophys. 2006;45(1):9–16.
5. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2008;105(20):7269–74.
6. Gao L, Zhu X, Li Z, Li L, Wang T, et al. Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma. Tumour Biol. 2014;35(4):3861–5.
7. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell. 2013;24(5):617–30.
8. Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 2005;83(1):1–14.
9. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3 K/AKT pathway during tumor maintenance. Cancer Cell. 2005;8(5):381–92.
10. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 2005;7(6):533–45.
11. Zou M, Baitei EY, Alzahrani AS, Humaid FB, Alkhafaji DM, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014.
12. Park JY, Kim WY, Hwang TS, Lee SS, Kim H, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013;24(2):69–76.
13. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276–85.
14. Park SJ, Sun JY, Hong K, Kwak JY, Kim EK, et al. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Clin Chem Lab Med. 2013;51(8):1673–80.
15. Myers MB, McKim KL, Parsons BL. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid. Mol Carcinog. 2014;53(2):159–67.
16. Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, et al. Extensive sequence variation in the 3′ untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle. 2014;13(6):1030–40.
17. Wang XF, Shi ZM, Wang XR, Cao L, Wang YY, et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol. 2012;138(4):573–84.
18. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39(5):673–7.
19. Wang WY, Chien YC, Wong YK, Lin YL, Lin JC. Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma. Head Neck. 2012;34(5):663–6.
20. Li ZH, Pan XM, Han BW, Guo XM, Zhang Z, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34(5):3159–63.
21. Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 2014;35(1):831–5.
22. Pan XM, Jia J, Guo XM, Li ZH, Zhang Z, et al. Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma. Fam Cancer. 2014;13(1):93–7.
23. Rajewsky N. microRNA target predictions in animals. Nat Genet. 2006;38:S8–13.
24. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500.
25. Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2014;96(1):98–107.
26. Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis. 2008;67(5):677–82.
27. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
28. Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, et al. Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother. 2007;61(10):640–58.
29. Belpomme D, Irigaray P, Sasco AJ, Newby JA, Howard V, et al. The growing incidence of cancer: role of lifestyle and screening detection (Review). Int J Oncol. 2007;30(5):1037–49.
30. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004;14(6):473–86.
31. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–47.